Basic Information
Sunlenca
Regulatory Information
EMEA/H/C/005638
August 17, 2022
June 23, 2022
5
October 16, 2024
Company Information
Ireland
Ida Business And Technology Park Carrigtohill Co Cork T45 DP77
GILEAD SCIENCES IRELAND UNLIMITED COMPANY
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication **Sunlenca injection**, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1). **Sunlenca tablet**, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1).
Overview Summary
Sunlenca is used, together with other medicines, to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). Sunlenca is given when the virus is resistant to other treatments. Sunlenca contains the active substance lenacapavir.